Silvercrest Asset Management’s Cogent Biosciences COGT Stock Holding History

Silvercrest Asset Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.17M	Buy	+159,545	New	+$5.58M	0.04%	421

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silvercrest Asset Management's COGT Position: Q2 2026 in Review

Silvercrest Asset Management opened a new position in Cogent Biosciences (COGT) in Q2 2026: 159,545 shares worth $6.17M. The stake represents 0.04% of the portfolio and ranks #421 among its holdings.

322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Silvercrest Asset Management held 159,545 shares of Cogent Biosciences worth $6.17M as of Q2 2026.
Cogent Biosciences was a new Silvercrest Asset Management position in Q2 2026.
Cogent Biosciences made up 0.04% of Silvercrest Asset Management's portfolio in Q2 2026, its #421 holding.
322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.